MAIA Biotechnology (NYSE American: MAIA) outlined its strategy to address a significant unmet need in oncology through its lead asset, atevagenosine (THIO), a differentiated cancer…
December 10, 2025
MAIA Biotechnology (NYSE American: MAIA) outlined its strategy to address a significant unmet need in oncology through its lead asset, atevagenosine (THIO), a differentiated cancer…